Andere talen Cartesian Therapeutics, Inc.

Aandelen

RNAC

US8162123025

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
17,91 ^USD	+3,65%		-7,63%	-13,40%

14/03	Cartesian Therapeutics, Inc ontvangt bericht van Audentes Therapeutics, Inc van Astellas? Beëindiging van de licentie- en ontwikkelingsovereenkomst	CI
07/03	Cartesian Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04/04
Cartesian Therapeutics Announces New Employment Inducement Grants	04/04
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split	28/03
Cartesian Therapeutics : Termination of Material Agreement - Form 8-K	14/03
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	14/03
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	07/03
Cartesian Therapeutics to Participate in Upcoming Investor Conferences	06/03
Cartesian Therapeutics Announces New Employment Inducement Grant	05/03
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	05/03
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05/03
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05/03
Cartesian Therapeutics Announces New Employment Inducement Grants	05/02
Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm	18/01
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity	08/01
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	08/01
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	08/01
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) dropped from NASDAQ Biotechnology Index	15/12
Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees	27/11
North American Morning Briefing : Stock Futures -2-	16/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cartesian Therapeutics, Inc.

Aandelen

RNAC

US8162123025

Andere talen

Filters